ROCHE DIAGNOSTICS LIMITED

Location

Founded

1956-09-14

Website

https://diagnostics.roche.com

Risk Signals

24759 news mentions monitored

Industry Context

This company is tracked across risk categories, including those related to its sector (e.g., Business Services, Not Elsewhere Classified), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.

Filter risk signals by topic

Select a theme below to explore the company’s news mentions in specific risk areas.

Corporate Insolvency Insolvency Risks Tax Compliance Violations Asset Seizure Workforce Reductions Ethics Violations Allegations Financial Reporting Irregularities Insider Trading Violations Explosion and Gas Leak Incidents Fire Incident Impact Logistics & Transportation Disruptions Illicit Financial Practices Offshore Tax Practices Legal Scandals Labor Exploitation Government Corruption Product Quality Compliance Safety Compliance Violations Product Recall Regulatory and Legal Emergencies Corporate Fraud Corporate Financial Crises Fraud Investigations Child Labor Violations Financial Crime Investigations Financial Statement Revisions Debt Strategy and Obligations Activist Short Selling Investor Sentiment Trends War

Recent Articles about ROCHE DIAGNOSTICS LIMITED

Live alerts from global media, monitored by Business Radar

2025-07-10 (dailyhealthindustry.it)

10 Luglio 2025 – Pagina Array – Daily Health Industry

In a country that focuses on competitiveness and innovation to build its future, the biotech sector is confirmed as a pillar of the Italian economy. This is demonstrated by the first impact study carried out with the methodological support of PWC Italia and which analyzes the value generated by a pharmaceutical company, Roche, in four areas: economics, research, work and environment. The results were ...

2025-07-10 (tt.se)

Parse-Enabled Study Maps Neuronal Pathways with Potential Implications for Neurodegenerative Disease Research | Business Wire

Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced a groundbreaking study published in the journal Science that utilized Parse's single cell technology to uncover how signaling pathways drive the formation of diverse neuron cell subtypes. By linking specific signals to cell fate outcomes, this research provides a powerful framework for generating defined cell types in vitro, which has broad relevance to human biology, disease, and therapeutic development. Principle investigators Dr. Barbara Treutlein, Head of the Quantitative Development Biology Lab at ETH Zurich, and Dr. Gray Camp, Group Leader at the Institute of Human Biology at Roche, led the experiment. Through an elegantly designed screening approach spanning 480 morphogens across 700,000 cells, the research team was able to explore how different morphogens interact with pro-neural transcription factors, thereby generating pure populations of different types of neu

2025-07-10 (elsiglofuturo.es)

El Siglo Future - Biotech, from Roche 700 million contribution to Italian GDP

Every euro of direct added value generates 2.26 per economy

2025-07-10 (koreabiomed.com)

Korean health agency recognizes HER2 companion diagnostic tests as Level 2 reimbursement target < Policy < Article -

The Health Insurance Review and Assessment Service (HIRA) has officially determined that the "Level 2" companion diagnosis reimbursement is appropriate for the HER2 (Human Epidermal growth factor Receptor 2) companion diagnostic immunohistochemical (IHC) test, which has been a key concern for pathol